Abstract
It remains unclear how the immune system affects leukemia development. To clarify the significance of the presence of immune systems in leukemia development, we transferred MLL/ENL leukemia cells into immune-competent or immune-deficient mice without any preconditioning including irradiation. The wild-type mice did not develop leukemia, whereas all the Rag2−/−γc−/− mice lacking both adaptive immune cells and natural killer (NK) cells developed leukemia, indicating that leukemia cells were immunologically rejected. Interestingly, leukemia cells were also rejected in 60% of the Rag2−/− mice that lacked adaptive immune cells but possessed NK cells, suggesting that NK cells play a substantial role in the rejection of leukemia. Moreover, engraftment of leukemia cells was enhanced by NK cell depletion in Rag2−/− recipients and inhibited by transfer of NK cells into Rag2−/−γc−/− recipients. Upregulation of NKG2D (NK group 2, member D) ligands in MLL/ENL leukemia cells caused elimination of leukemia cells by NK cells. Finally, we found that leukemia cells resistant to elimination by NK cells had been selected during leukemia development in Rag2−/− recipients. These results demonstrate that NK cells can eradicate MLL/ENL leukemia cells in vivo in the absence of adaptive immunity, thus suggesting that NK cells can play a potent role in immunosurveillance against leukemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Burnet M . Cancer: a biological approach III. Viruses associated with neoplastic conditions. IV. Practical applications. BMJ 1957; 1: 841–847.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991–998.
Schreiber RD, Old LJ, Smyth MJ . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565–1570.
Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482: 400–404.
DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T . Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012; 482: 405–409.
van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996; 184: 1781–1790.
Street SE, Cretney E, Smyth MJ . Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001; 97: 192–197.
Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ . Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168: 1356–1361.
Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28: 571–580.
Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008; 205: 2965–2973.
Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 2008; 205: 2959–2964.
Elboim M, Gazit R, Gur C, Ghadially H, Betser-Cohen G, Mandelboim O . Tumor immunoediting by NKp46. J Immunol 2010; 184: 5637–5644.
Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885–13890.
Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997; 90: 2529–2534.
Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM . A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 1999; 59: 2675–2681.
Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102: 1389–1396.
Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005; 105: 2066–2073.
Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012; 189: 1360–1371.
Tkachuk DC, Kohler S, Cleary ML . Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992; 71: 691–700.
Slany RK, Lavau C, Cleary ML . The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol 1998; 18: 122–129.
Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL . Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17: 3029–3035.
Morita S, Kojima T, Kitamura T . Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 2000; 7: 1063–1066.
Lavau C, Szilvassy SJ, Slany R, Cleary ML . Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 1997; 16: 4226–4237.
Somervaille TC, Cleary ML . Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006; 10: 257–268.
Hamby K, Trexler A, Pearson TC, Larsen CP, Rigby MR, Kean LS . NK cells rapidly reject allogeneic bone marrow in the spleen through a perforin- and Ly49D-dependent, but NKG2D-independent mechanism. Am J Transplant 2007; 7: 1884–1896.
Di Santo JP . Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 2006; 24: 257–286.
Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L . Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012; 12: 239–252.
Raulet DH . Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3: 781–790.
Raulet DH, Guerra N . Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009; 9: 568–580.
Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331: 44–49.
Mooney JM, Klem J, Wulfing C, Mijares LA, Schwartzberg PL, Bennett M et al. The murine NK receptor 2B4 (CD244) exhibits inhibitory function independent of signaling lymphocytic activation molecule-associated protein expression. J Immunol 2004; 173: 3953–3961.
Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D . Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 1999; 6: 1305–1312.
Rosenzweig M, Connole M, Glickman R, Yue SP, Noren B, DeMaria M et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells. Blood 2001; 97: 1951–1959.
Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L . Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 2004; 103: 3700–3709.
Unni AM, Bondar T, Medzhitov R . Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc Natl Acad Sci USA 2008; 105: 1686–1691.
Cerwenka A, Baron JL, Lanier LL . Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001; 98: 11521–11526.
Diefenbach A, Jensen ER, Jamieson AM, Raulet DH . Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165–171.
Ogasawara K, Benjamin J, Takaki R, Phillips JH, Lanier LL . Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat Immunol 2005; 6: 938–945.
Smyth MJ, Hayakawa Y, Takeda K, Yagita H . New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2: 850–861.
Zhang C, Zhang J, Tian Z . The regulatory effect of natural killer cells: do ‘NK-reg cells’ exist? Cell Mol Immunol 2006; 3: 241–254.
Benson DM Jr., Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 2011; 118: 6387–6391.
Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012; 120: 4317–4323.
Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008; 111: 1428–1436.
Tang KF, He CX, Zeng GL, Wu J, Song GB, Shi YS et al. Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine. Biochem Biophys Res Commun 2008; 370: 578–583.
Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009; 113: 3503–3511.
Acknowledgements
We thanks Irving L Weissman (Stanford University) for kind gifts of Rag2−/−γc−/− mice, Michael L Cleary (Stanford University) for kind gift of MLL/ENL cDNA, Toshio Kitamura (Tokyo University) for kind gift of Plat-E cells, Hisashi Arase (Osaka University) for fruitful discussion and Ruriko Inoue (Osaka University) for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Nakata, J., Nakano, K., Okumura, A. et al. In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity. Leukemia 28, 1316–1325 (2014). https://doi.org/10.1038/leu.2013.374
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.374
Keywords
This article is cited by
-
Hyperactive Natural Killer cells in Rag2 knockout mice inhibit the development of acute myeloid leukemia
Communications Biology (2023)
-
ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia
Cellular and Molecular Life Sciences (2018)
-
NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions
Science China Life Sciences (2015)